 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes SULFADIAZINE increase or decrease the risk of acute liver [0m
[34minjury?[0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does SULFADIAZINE increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes SULFADIAZINE increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes SULFADIAZINE increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does SULFADIAZINE increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"SULFADIAZINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: SULFADIAZINE: warnings: WARNINGS Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported,[0m
[31mit is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including [0m
[31magranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [0m[1;31m[[0m[31mStevens-Johnson syndrome [0m
[1;31m([0m[31mSJS[0m[1;31m)[0m[31m, toxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m and exfoliative dermatitis[0m[1;31m][0m[31m; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis. There is a potential [0m
[31mcross-sensitivity between silver sulfadiazine and other sulfonamides. SULFADIAZINE: warnings: If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy [0m
[31mmust be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal [0m
[31msuperinfection is low. The use of silver sulfadiazine cream, USP [0m[1;31m1[0m[31m% in some cases of glucose-[0m[1;31m6[0m[31m-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.         [0m
[31mSOURCE:SULFADIAZINE label[0m


[31mCONTENT: SULFADIAZINE: dosage_and_administration: DOSAGE AND ADMINISTRATION Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of[0m
[31mshock and pain. The burn wounds are then cleansed and debrided; silver sulfadiazine cream, USP [0m[1;31m1[0m[31m% is then applied under sterile conditions. The burn areas should be covered with silver sulfadiazine [0m
[31mcream, USP [0m[1;31m1[0m[31m% at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas [0m
[31mfrom which it has been removed by patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings [0m
[31mnecessary, they may be used. Reapply immediately after hydrotherapy. Treatment with silver sulfadiazine cream, USP [0m[1;31m1[0m[31m% should be continued until satisfactory healing has occurred or until the burn site[0m
[31mis ready for grafting. SULFADIAZINE: dosage_and_administration: The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant [0m
[31madverse reaction occurs.         [0m
[31mSOURCE:SULFADIAZINE label[0m


[31mCONTENT: SULFADIAZINE: openfda: package_ndc         [0m
[31mSOURCE:SULFADIAZINE label[0m


[31mCONTENT: SULFADIAZINE: adverse_reactions: ADVERSE REACTIONS Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. [0m[1;31m1[0m[31m,[0m[1;31m2[0m[31m,[0m[1;31m3[0m[31m Leukopenia associated with[0m
[31msilver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to [0m
[31mnormal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. An increased incidence has been seen in patients treated [0m
[31mconcurrently with cimetidine. Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in [0m
[31mbacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial-thickness burns by preventing conversion of the partial thickness to [0m
[31mfull thickness by sepsis. SULFADIAZINE: adverse_reactions: However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent [0m
[31mcontracture.         [0m
[31mSOURCE:SULFADIAZINE label[0m


[31mCONTENT: SULFADIAZINE: pregnancy: PREGNANCY: TERATOGENIC EFFECTS: Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver[0m
[31msulfadiazine in silver sulfadiazine cream, USP [0m[1;31m1[0m[31m% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant [0m
[31mwomen. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or[0m
[31mat term. SULFADIAZINE: pregnancy: [0m[1;31m([0m[31mSee CONTRAINDICATIONS [0m[1;31m)[0m[31m         [0m
[31mSOURCE:SULFADIAZINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Sulfadiazine, particularly in the form of silver sulfadiazine, has been associated with various adverse reactions, including hepatitis and hepatocellular necrosis, which are indicative of [0m
[32mliver injury. However, the extracts do not specify the frequency or the risk increase of acute liver injury due to sulfadiazine.[0m

[32mSOURCE: SULFADIAZINE label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mgastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions[0m[32m...[0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Sulfadiazine, particularly in the form of silver [0m
[34msulfadiazine, has been associated with various adverse reactions, including hepatitis and hepatocellular necrosis, which are indicative of liver injury. However, the extracts do not specify the [0m
[34mfrequency or the risk increase of acute liver injury due to sulfadiazine.[0m

[34mSOURCE: SULFADIAZINE label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mgastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions[0m[34m...[0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does SULFADIAZINE increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if SULFADIAZINE increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that SULFADIAZINE, particularly in the form of silver sulfadiazine, has been associated with various adverse reactions, including hepatitis and hepatocellular necrosis, [0m
[32mwhich are indicative of liver injury."[0m[32m,[0m
[32m      [0m[32m"The FDAHandler's response indicates an association but does not specify the frequency or the risk increase of acute liver injury due to sulfadiazine."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"SULFADIAZINE has been associated with adverse reactions indicative of liver injury, such as hepatitis and hepatocellular necrosis. However, the frequency or degree of increased risk of [0m
[32macute liver injury due to sulfadiazine is not specified."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does SULFADIAZINE increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if SULFADIAZINE increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that SULFADIAZINE, particularly in the form of silver sulfadiazine, has been associated with various adverse reactions, including hepatitis and hepatocellular necrosis, [0m
[34mwhich are indicative of liver injury."[0m[34m,[0m
[34m      [0m[34m"The FDAHandler's response indicates an association but does not specify the frequency or the risk increase of acute liver injury due to sulfadiazine."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"SULFADIAZINE has been associated with adverse reactions indicative of liver injury, such as hepatitis and hepatocellular necrosis. However, the frequency or degree of increased risk of [0m
[34macute liver injury due to sulfadiazine is not specified."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does SULFADIAZINE increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if SULFADIAZINE increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that SULFADIAZINE, particularly in the form of silver sulfadiazine, has been associated with various adverse reactions, including hepatitis and hepatocellular necrosis, which [0m
[31mare indicative of liver injury.[0m
[1;31m3[0m[31m. The FDAHandler's response indicates an association but does not specify the frequency or the risk increase of acute liver injury due to sulfadiazine.[0m
[31m        -----[0m
[31m        Final answer: SULFADIAZINE has been associated with adverse reactions indicative of liver injury, such as hepatitis and hepatocellular necrosis. However, the frequency or degree of increased [0m
[31mrisk of acute liver injury due to sulfadiazine is not specified.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-SULFADIAZINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mSULFADIAZINE has been associated with adverse reactions indicative of liver injury, such as hepatitis and hepatocellular necrosis. However, the frequency or degree of increased risk of acute liver [0m
[32minjury due to sulfadiazine is not specified.[0m
